Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office
April 22, 2024 08:30 ET
|
Adial Pharmaceuticals, Inc
GLEN ALLEN, Va., April 22, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
April 10, 2024 08:30 ET
|
Adial Pharmaceuticals, Inc
GLEN ALLEN, Va., April 10, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...
Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update
April 02, 2024 08:30 ET
|
Adial Pharmaceuticals, Inc
Received Favorable Feedback from US and EU Regulatory Agencies Advancing Discussions with Potential Strategic Partners Received $4.3 Million in Gross Proceeds from Warrant Exercises Subsequent to...
Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds
March 01, 2024 19:00 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., March 01, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office
February 28, 2024 09:30 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office
February 13, 2024 09:15 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Announces Appointment of Tony Goodman as Chief Operating Officer
January 18, 2024 08:30 ET
|
Adial Pharmaceuticals, Inc
Charlottesville, Va., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Receives Final Reimbursement Payment from Adovate
December 20, 2023 09:00 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement
November 29, 2023 16:05 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
November 14, 2023 17:02 ET
|
Adial Pharmaceuticals, Inc
Advancing Discussions with Potential Strategic Partners Received Frost & Sullivan’s 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award ...